(31) reported that EVI1-induced hypermethylation and downregulation of miR-9 play an important role in leukemogenesis in pediatric patients with AML and EVI1high, indicating that hypomethylating agents may be a potential therapeutic strategy for these patients. This evidence concerns the gene MECOM and acute myeloid leukemia.